[Molecular Genetic Analysis and Clinical Aspects of Patients with Hereditary Hemochromatosis]

Overview

Journal Orthopade

Specialty Orthopedics

Date 2014 Jun 8

PMID 24906241

Authors

U Lange

J Teichmann

G Dischereit

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of the study was to perform a molecular genetic analysis and to document clinical aspects in patients with hereditary hemochromatosis.

Patients And Methods: The study included 33 outpatients (23 males average age 50.6 years and 10 females average age 60.6 years) with a disorder of iron metabolism (transferrin saturation > 75 %) as confirmation of hemochromatosis who were subjected to molecular genetic and clinical analyses.

Results: A homozygous mutation of the hemochromatosis (HFE) gene (C282YY) was detected in 63.6 %, a compound heterozygous mutation (C282Y/H63D) in 30.3% and no mutation of the HFE gene was detected in 6.1 %. The following organ manifestations could be objectified: arthralgia (78.8 %), liver disease (39.9 %), skin hyperpigmentation (30.3 %), osteoporosis (24.2 %), diabetes mellitus (24.2 %) and cardiomyopathy (12.1 %). Comparison between patients with heterozygous and homozygous hemochromatosis revealed the following differences: compound heterozygote patients presented less frequently with osteoarthritis of the metacarpophalangeal (MCP) joints and hands (85.7 %/71.4 % homozygotes vs. 60 %/60 % heterozygotes). Osteoarthritis of the shoulder joints and osteoporosis as well as hypothyroidism were more frequent in compound heterozygote patients, whereas osteoarthritis of the knee and hip joints as well as liver disease were more common in homozygote patients. No differences between both groups were seen with respect to the clinical manifestations of cardiomyopathy and diabetes mellitus.

Conclusion: Prevalent causes of death in hereditary hemochromatosis are heart failure, liver disease (cirrhosis and hepatocellular carcinoma) and portal hypertension. Therefore, an early diagnosis, adequate therapy and genetic screening of family members are of great importance. Medicinal treatment will only effectively prevent deleterious organ involvement and subsequent complications if initiated at an early stage. Furthermore, an overview of the current data is given.

References

Rivers J, Garrahy P, Robinson W, Murphy A . Reversible cardiac dysfunction in hemochromatosis. Am Heart J. 1987; 113(1):216-7. DOI: 10.1016/0002-8703(87)90039-1. View

Bulaj Z, Ajioka R, Phillips J, LaSalle B, Jorde L, Griffen L . Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000; 343(21):1529-35. DOI: 10.1056/NEJM200011233432104. View

Salonen J, Tuomainen T, Kontula K . Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. BMJ. 2000; 320(7251):1706-7. PMC: 27415. DOI: 10.1136/bmj.320.7251.1706. View

Fracanzani A, Fargion S, Romano R, Conte D, Piperno A, DAlba R . Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology. 1995; 22(4 Pt 1):1127-31. DOI: 10.1002/hep.1840220417. View

Dymock I, HAMILTON E, LAWS J, Williams R . Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis. 1970; 29(5):469-76. PMC: 1010558. DOI: 10.1136/ard.29.5.469. View

Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M . Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med. 1998; 128(5):370-3. DOI: 10.7326/0003-4819-128-5-199803010-00005. View

Diamond T, Stiel D, Posen S . Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?. Ann Intern Med. 1989; 110(6):430-6. DOI: 10.7326/0003-4819-110-6-430. View

Faraawi R, Harth M, Kertesz A, Bell D . Arthritis in hemochromatosis. J Rheumatol. 1993; 20(3):448-52. View

Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R . Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2004; 125(6):1733-41. DOI: 10.1053/j.gastro.2003.09.035. View

10.

Allen K, Gurrin L, Constantine C, Osborne N, Delatycki M, Nicoll A . Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008; 358(3):221-30. DOI: 10.1056/NEJMoa073286. View

11.

Frayling T, Ellard S, Grove J, Walker M, Hattersley A . C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet. 1998; 351(9120):1933-4. DOI: 10.1016/S0140-6736(05)78618-9. View

12.

Pippard M . Detection of iron overload. Lancet. 1997; 349(9045):73-4. DOI: 10.1016/S0140-6736(05)60880-X. View

13.

Tuomainen T, Kontula K, Nyyssonen K, Lakka T, Helio T, Salonen J . Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation. 1999; 100(12):1274-9. DOI: 10.1161/01.cir.100.12.1274. View

14.

Nelson R, Davis F, Persky V, Becker E . Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer. 1995; 76(5):875-9. DOI: 10.1002/1097-0142(19950901)76:5<875::aid-cncr2820760523>3.0.co;2-q. View

15.

SMITH Jr L . Overview of hemochromatosis. West J Med. 1990; 153(3):296-308. PMC: 1002534. View

16.

Waalen J, Felitti V, Gelbart T, Ho N, Beutler E . Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002; 113(6):472-9. DOI: 10.1016/s0002-9343(02)01249-4. View

17.

Edwards C, Kushner J . Screening for hemochromatosis. N Engl J Med. 1993; 328(22):1616-20. DOI: 10.1056/NEJM199306033282208. View

18.

Ellervik C, Mandrup-Poulsen T, Nordestgaard B, Larsen L, Appleyard M, Frandsen M . Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001; 358(9291):1405-9. DOI: 10.1016/S0140-6736(01)06526-6. View

19.

Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E . Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood. 2007; 110(12):4096-100. DOI: 10.1182/blood-2007-06-096503. View

20.

Niederau C, Niederau C, Lange S, Littauer A, Maurer M, Haussinger D . Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998; 128(5):337-45. DOI: 10.7326/0003-4819-128-5-199803010-00001. View